Stem Cell Business Models with Bill Kridel

BioBusiness.TV, the podcast! ver2

You are Watching: Stem Cells Business Models, FDA Initiatives, Companies, and Funds, with Bill Kridel Bill Kridel compares stem cell business models that rely on allogenic vs autologous cells and discusses their market potential. He also touches at the various uses of stem cells, the need for standards of uniformity, FDA Initiatives, companies to focus on, and specialized funds. This interview was conducted at the NASDAQ Marketsite, on July 23rd, 2008, in New York City. Featuring: * William Kridel, Managing Director at Ferghana Partners Group * Jean-Loup Romet-Lemonne, President & CEO of BioBusiness.TV DISCLAIMER: BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS. BIOBUSINESS.TV STRIVES TO ENHANCE THE QUALITY AND ACCESSIBILITY OF INDUSTRY DATA, AND TO DELIVER INFORMATION THAT INVESTORS AND EXECUTIVES CAN RELY UPON TO MAKE SOUND, INFORMED FINANCIAL AND MANAGERIAL DECISIONS. VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.